Renal cyclooxygenase-2 in obese Zucker (fatty) rats
Language English Country United States Media print
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
Grant support
DK 63231
NIDDK NIH HHS - United States
PubMed
15882258
DOI
10.1111/j.1523-1755.2005.00320.x
PII: S0085-2538(15)50704-7
Knihovny.cz E-resources
- MeSH
- Androstadienes pharmacology MeSH
- Cyclooxygenase 1 MeSH
- Cyclooxygenase 2 MeSH
- Prostaglandin-Endoperoxide Synthases analysis physiology MeSH
- Dinoprostone biosynthesis MeSH
- Rats MeSH
- Fatty Acids, Nonesterified blood MeSH
- Kidney enzymology MeSH
- Membrane Proteins MeSH
- Obesity enzymology MeSH
- Rats, Zucker MeSH
- Thromboxane B2 biosynthesis MeSH
- Wortmannin MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, U.S. Gov't, P.H.S. MeSH
- Names of Substances
- Androstadienes MeSH
- Cyclooxygenase 1 MeSH
- Cyclooxygenase 2 MeSH
- Prostaglandin-Endoperoxide Synthases MeSH
- Dinoprostone MeSH
- Fatty Acids, Nonesterified MeSH
- Membrane Proteins MeSH
- Ptgs1 protein, rat MeSH Browser
- Thromboxane B2 MeSH
- Wortmannin MeSH
BACKGROUND: Cyclooxygenase (COX) isoforms, COX-1 and COX-2, are involved in production of prostanoids in the kidney. Increases in renal COX-2 expression have been implicated in the pathophysiology of progressive renal injury, including type 1 diabetes. Thromboxane A(2) (TxA(2)) has been suggested as the key mediator of these effects resulting in up-regulation of prosclerotic cytokines and extracellular matrix proteins. Unlike type 1 diabetes, renal COX has not been studied in models of type 2 diabetes. METHODS: Renal cortical COX protein expression, and urinary excretion of stable metabolites of prostaglandin E(2) (PGE(2)) and TxA(2), in association with metabolic parameters, were determined in 4-and 12-week-old Zucker fatty rats (fa/fa rat) (ZDF4 and ZDF12), a model of type 2 diabetes, and in age-matched littermates with no metabolic defect (Zucker lean) (ZL4 and ZL12). RESULTS: Western blotting revealed increased COX-2 expression in ZDF4 as compared to ZL4 (245 +/- 130%) (P < 0.05). This increase in COX-2 was even more apparent in 12-week-old ZDF rats (650 +/- 120%) (P < 0.01). All groups of rats demonstrated COX-2-positive cells in typical cortical localizations [macula densa, thick ascending loop of Henle (TALH)]. In contrast to COX-2, COX-1 expression was 30% lower in ZDF12. These changes in COX expression were associated with enhanced urinary excretion of prostanoids, in parallel with the development of metabolic abnormalities. Moreover, increases in prostanoid excretion in ZDF12 were in part reduced by wortmannin (100 mug/kg), used as inhibitor of insulin signaling. CONCLUSION: Renal cortical COX-2 protein expression and function were increased in ZDF rats, as compared to controls, whereas COX-1 exhibited opposite regulation. The changes in COX-2 paralleled metabolic abnormalities, and were at least in part a four consequence of hyperinsulinemia. These abnormalities may play a role in renal pathophysiology in this model of type 2 diabetes.
References provided by Crossref.org